There have been significant evidence-based literature updates regarding the management of acute ischemic stroke (AIS) in adult patients; these are discussed in a 2018 guideline update.
This drug class confers benefits in diabetic patients with heart failure, CV disease, and renal disease, but it is also associated with major adverse events.